Prescription medicine
Apixaban Brand names: Eliquis
Apixaban (Eliquis) is a prescription medicine with an FDA approval on record since 2012. A generic is approved and listed by 2 labelers, but in the October 7, 2026 NADAC survey pharmacies bought only the brand, at $5.52 per Eliquis 5 mg tablet.
- Generic approved
- Boxed warning
Check it at the source: the apixaban FDA label on DailyMed (effective April 24, 2026, Cardinal Health 107, LLC); the NDA 202155 record on Drugs@FDA; every apixaban label on DailyMed.
Highlights of the record
FDA label of April 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS; (B) SPINAL/EPIDURAL HEMATOMA.
Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Studies (14.1) ]. (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. […]
Used for
From the label: indications and usageELIQUIS is a factor Xa inhibitor indicated:
to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.
Forms and strengths
- 0.15 mg
- 0.5 mg
- 2.5 mg
- 5 mg
Film-coated tablet; kit; tablet for suspension; capsule.
On the market
- Earliest approval on file
- December 28, 2012 Eliquis, Bristol Myers Squibb; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 13 first December 23, 2019; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 8 of which 2 under generic applications, 6 under brand applications, repackagers included
- Last listed patent
- August 24, 2031 Eliquis tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $5.52 per tablet Eliquis 5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 66,522 through July 30, 2026
What is apixaban used for?
From the label: indications and usageELIQUIS is a factor Xa inhibitor indicated:
to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1)
for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2)
for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5)
Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. […]
Conditions named in the indications of apixaban's FDA labels, with every medicine labeled for each:
From other apixaban labelsStroke prevention: Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.
FDA pharmacologic class: Factor Xa Inhibitor.
Source: FDA drug label (ELIQUIS), NDA202155 (Bristol Myers Squibb), as published by Cardinal Health 107, LLC, effective April 24, 2026 (SPL set a454cd24-0c6d-46e8-b1e4-197388606175), via openFDA; the full label on DailyMed
What does the patient leaflet for apixaban say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about ELIQUIS?ELIQUIS may cause serious side effects, including: • Increased risk of blood clots if you stop taking ELIQUIS. ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have increased risk of forming a clot in your blood. Do not stop taking ELIQUIS without talking to the healthcare provider who prescribes it for you. Stopping ELIQUIS increases your risk of having a stroke. ELIQUIS may need to be stopped, if possible, prior to surgery or a medical or dental procedure. Ask the healthcare provider who prescribed ELIQUIS for you when you should stop taking it. Your healthcare provider will tell you when you may start taking ELIQUIS again after your surgery or procedure. If you have to stop taking ELIQUIS, your healthcare provider may prescribe another medicine to help prevent a blood clot from forming. • Increased risk of bleeding. ELIQUIS can cause bleeding which can be serious and may lead to death. […] it may take longer than usual for any bleeding to stop Call your healthcare provider or get medical help right away if you or your child develop any of these signs or symptoms of bleeding during treatment with ELIQUIS: • unexpected bleeding or bruising, or bleeding that lasts a long time, such as: o unusual bleeding from the gums o nosebleeds that happen often o menstrual bleeding or vaginal bleeding that is heavier than normal • bleeding that is severe or you cannot control • red, pink, or brown urine • red or black stools (looks like tar) • cough up blood or blood clots • vomit blood or your vomit looks like “coffee grounds” • unexpected pain, swelling, or joint pain • headaches, feeling dizzy or weak • Spinal or epidural blood clots (hematoma). […]
From the patient leaflet: How should I store ELIQUIS?Store ELIQUIS at room temperature between 68°F to 77°F (20°C to 25°C). Keep ELIQUIS and all medicines out of the reach of children. General Information about the safe and effective use of ELIQUIS. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ELIQUIS that is written for health professionals.
Source: FDA drug label (ELIQUIS), NDA202155 (Bristol Myers Squibb), as published by Cardinal Health 107, LLC, effective April 24, 2026 (SPL set a454cd24-0c6d-46e8-b1e4-197388606175), via openFDA; the full label on DailyMed
Is there a generic for apixaban (Eliquis)?
The FDA approved the first generic apixaban on December 23, 2019. 13 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 10 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists apixaban from 2 labelers under a generic (ANDA) application and from 6 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it. In the latest NADAC survey pharmacies bought only the brand, so a generic may not be on sale yet.
The Orange Book lists 2 patents for Eliquis tablets: the compound patent runs to November 21, 2026 (pediatric exclusivity to May 21, 2027), and the last listed entry to August 24, 2031; a patent listed only for Eliquis Sprinkle for oral suspension runs to May 22, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2012 earliest approval on file
- 2019 first generic approved
- 2031 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for apixaban (Eliquis)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $5.52 per Eliquis 5 mg tablet, down 43% from $9.69 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Eliquis 5 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Eliquis 2.5 mg tablet | Brand | $5.51 per tablet | $165.38 | -43% |
| Eliquis 5 mg tablet | Brand | $5.52 per tablet | $165.63 | -43% |
| Eliquis DVT-PE treatment 30-day starter 5 mg pack | Brand | $5.51 per unit | n/a | -43% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the apixaban label say about other medicines?
The apixaban label names 16 other medicines in its interaction, contraindication or warning sections. The labels of 18 other medicines name apixaban. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aminocaproic acid | warnings and precautions | There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. |
| Andexanet alfa | warnings and precautions | Reversal of Anticoagulant Effect A specific reversal agent (andexanet alfa) antagonizing the pharmacodynamic effect of apixaban is available for adults. |
| Aspirin | drug interactions | Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. |
| Carbamazepine | drug interactions | Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3) ]. |
| Clarithromycin | drug interactions | Clarithromycin Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS [see Clinical Pharmacology (12.3) ]. |
| Clopidogrel | drug interactions | APPRAISE-2, a placebo-controlled clinical trial of ELIQUIS in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with ELIQUIS compared to placebo. |
| Desmopressin | warnings and precautions | There is no experience with systemic hemostatics (desmopressin) in individuals receiving ELIQUIS, and they are not expected to be effective as a reversal agent. |
| Heparin | drug interactions | Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. |
| Itraconazole | drug interactions | For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ]. |
| Ketoconazole | drug interactions | For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ]. |
| Phenytoin | drug interactions | Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3) ]. |
| Protamine | warnings and precautions | Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. |
| Rifampin | drug interactions | Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3) ]. |
| Ritonavir | drug interactions | For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ]. |
Every other medicine the apixaban label names
| Medicine named | Section | What the label says |
|---|---|---|
| Tranexamic acid | warnings and precautions | There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. |
| Warfarin | drug interactions | In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% … |
Other labels that name apixaban
Source: FDA drug label (ELIQUIS), NDA202155 (Bristol Myers Squibb), as published by Cardinal Health 107, LLC, effective April 24, 2026 (SPL set a454cd24-0c6d-46e8-b1e4-197388606175), via openFDA; the full label on DailyMed
What do FAERS reports show for apixaban?
The FDA Adverse Event Reporting System holds 66,522 reports that list apixaban among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 7,220 are coded as a death and 29,310 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as apixaban?
4 other medicines are given the same way (oral) and in the same FDA class as apixaban or labeled mainly for the same use (atrial fibrillation), the same class first. Atrial fibrillation lists all 17 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Rivaroxaban | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | 20 labelers | $0.650 per tablet 2.5 mg tablet | A presentation being discontinued |
| Edoxaban | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | none listed | $15.51 per tablet 60 mg tablet | No current entry |
| Warfarin | Atrial fibrillation, Blood clots (DVT and PE) | 19 labelers | $0.093 per tablet 2 mg tablet | No current entry |
| Dabigatran | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | 16 labelers | $0.795 per capsule 150 mg capsule | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does apixaban compare with medicines for the same use?
5 side-by-side pages set apixaban beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to apixaban
- 4 medicines for the same use
- Other factor Xa inhibitors
- the pharmacologic class, with prices and generics
- Apixaban side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other